false 0001359931 0001359931 2024-06-07 2024-06-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 7, 2024

 

Protara Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-36694   20-4580525
(State or other jurisdiction
of incorporation)		   (Commission File No.)   (IRS Employer
Identification No.)

 

345 Park Avenue South

Third Floor

New York, NY

   10010
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (646) 844-0337

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading Symbol(s)

  

Name of each exchange on which registered

Common Stock, par value $0.001 per share   TARA   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

The Annual Meeting of Stockholders (the “Annual Meeting”) of Protara Therapeutics, Inc. (the “Company”) was held on June 7, 2024. As of April 11, 2024, the record date for the Annual Meeting, there were 20,578,425 shares of the Company’s common stock outstanding and entitled to vote.  A summary of the matters voted upon at the Annual Meeting and the final voting results are set forth below.

 

Proposal 1. Election of Directors.

 

The Company’s stockholders elected the three persons listed below as Class I directors, each to serve on the Company’s Board of Directors until the Company’s 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results are as follows:

 

   Votes For   Votes
Withheld		   Broker
Non-Votes		 
Jane Huang, M.D.   9,656,095    125,127    3,809,729 
Richard Levy, M.D.   9,642,092    139,130    3,809,729 
Michael Solomon, Ph.D.   9,560,752    220,470    3,809,729 

 

Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm.

 

The Company’s stockholders ratified the selection by the Company’s Audit Committee of the Board of Ernst and Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The final voting results are as follows:

 

Votes For   Votes Against   Abstentions
13,399,953   189,574   1,424

 

Proposal 3. Approval, on an Advisory Basis, of the Compensation of the Company’s Named Executive Officers.

 

The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Company’s definitive proxy statement for the Annual Meeting. The final voting results are as follows:

 

Votes For   Votes Against   Abstentions   Broker Non-Votes
6,999,091   196,457   2,585,674   3,809,729

 

Proposal 4. Approval of the Protara Therapeutics, Inc. 2024 Equity Incentive Plan.

 

The Company’s stockholders approved the adoption of the Protara Therapeutics, Inc. 2024 Equity Incentive Plan, as disclosed in the Company’s definitive proxy statement for the Annual Meeting. The final voting results are as follows:

 

Votes For   Votes Against   Abstentions   Broker Non-Votes
9,600,764   159,296   21,162   3,809,729

 

Proposal 5. Approval of the Protara Therapeutics, Inc. 2024 Employee Stock Purchase Plan.

 

The Company’s stockholders approved the adoption of the Protara Therapeutics, Inc. 2024 Employee Stock Purchase Plan, as disclosed in the Company’s definitive proxy statement for the Annual Meeting. The final voting results are as follows:

 

Votes For   Votes Against   Abstentions   Broker Non-Votes
9,650,650   128,502   2,070   3,809,729

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Protara Therapeutics, Inc.
     
Dated: June 10, 2024 By:

/s/ Patrick Fabbio

    Patrick Fabbio
    Chief Financial Officer

 

 

2

 

 

v3.24.1.1.u2
Cover
Jun. 07, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 07, 2024
Entity File Number 001-36694
Entity Registrant Name Protara Therapeutics, Inc.
Entity Central Index Key 0001359931
Entity Tax Identification Number 20-4580525
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 345 Park Avenue South
Entity Address, Address Line Two Third Floor
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10010
City Area Code 646
Local Phone Number 844-0337
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol TARA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
Von Mai 2024 bis Jun 2024 Click Here for more Protara Therapeutics Charts.
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
Von Jun 2023 bis Jun 2024 Click Here for more Protara Therapeutics Charts.